You are in: eMedicine Specialties > Emergency Medicine > TRAUMA AND ORTHOPEDICS Fracture, MandibleArticle Last Updated: Mar 6, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Thomas Widell, MD, Vice Chairman, Assistant Professor, Department of Emergency Medicine, Rosalind Franklin School of Medicine/The Chicago Medical School, North Chicago, Illinois; Associate Residency Director, University of Chicago Emergency Medicine Program, Chicago, Illinois; Program Director Emergency Medical Education, Attending Physician, Mount Sinai Hospital Medical Center, Chicago, Illinois Editors: Michelle Ervin, MD, Chair, Department of Emergency Medicine, Howard University Hospital; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Eric Legome, MD, Residency Director, Assistant Professor of Emergency Medicine, Department of Emergency Medicine New York University, New York University Hospital, Bellevue Hospital Center, Manhattan VA; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital Author and Editor Disclosure Synonyms and related keywords: mandible fracture, facial fracture, maxillofacial fractures, mandibular fractures, fractures of the mandible, high-impact mandibular fractures, low-impact mandibular fractures, maxillofacial injury, facial injury, jaw fracture INTRODUCTIONBackgroundHippocrates described an array of facial injuries as long ago as 400 BCE. In 1823, von Graeffe described the use of an elastic tube placed in the nares to maintain an open airway. During the early 20th century, Sir Harold Gilles, father of plastic surgery, taught army personnel about breathing problems in patients with facial injuries. He recommended positioning them supine to maintain an airway. Frenchman René Le Fort studied cadavers in 1901 and described 3 basic types of facial fractures. Endotracheal anesthesia and radiography, developed during the First World War, led to a better understanding and treatment of facial fractures. During the Second World War, a multidisciplinary approach to treatment of facial fractures continued to improve outcomes of severely injured soldiers. Advent of CT-guided reconstruction, along with new surgical techniques, has improved the final appearance of patients with bony injuries immensely. PathophysiologyMaxillofacial fractures are the result of blunt or penetrating trauma. Most are blunt injuries caused by vehicular crashes, altercations, sporting-related trauma, occupational injuries, and falls. Penetrating injuries are mainly the result of gunshot wounds, stabbings, and explosions. Determinants of type of injury (ie, soft tissue alone vs bony) are shape and velocity of the striking object. The amount of force needed to fracture different bones of the face has been studied, and these bones have been divided into those that require high impact to fracture (greater than 50 times the force of gravity [g]) and those that require only low impact to fracture (less than 50 g).
Mandibular fractures usually occur in 2 or more locations because of the bone's U shape and articulations at the temporomandibular joints. Fractures also may occur at a site apart from the site of direct trauma. A large percentage of mandibular fractures are open, as they often fracture between teeth and communicate with the oral cavity. Different mechanisms are associated with varying locations. Fractures from automobile crashes most frequently occur at the condyle and symphysis, those from motorcycle accidents at the symphysis and alveolus, and those from altercations mostly at the condyles, angles, and body. FrequencyUnited StatesThe mandible is the third most fractured bone of the face. Of these fractures, approximately 20-35% are at the condyle and ramus, 20-30% at the angle, 15-30% at the body, 8-20% at the symphysis, and 1-5% at the alveolar ridge. One study placed the incidence of severe maxillofacial injury (fractures, lacerations) at 0.04-0.09% for motor vehicle crashes. Incidence of fractures due to motor vehicle injuries is higher in rural areas; altercation-related injuries are more frequent in inner cities. Mortality/Morbidity
SexAdult male-to-female ratio is 3:1. Suspect domestic violence or sexual assault in women as this may coexist in 30% of cases. AgeMale predominance is reduced to 3:2 in children. In nonmotor vehicle injury, the possibility of child abuse should be a concern. CLINICALHistory
Physical
Causes
DIFFERENTIALSDislocations, Mandible Foreign Bodies, Trachea Fractures, Face Neck Trauma Pediatrics, Child Abuse
|
| Drug Name | Ibuprofen (Ibuprin, Advil, Motrin) |
|---|---|
| Description | Usually DOC for treatment of mild to moderately severe pain, if no contraindications. Inhibits inflammatory reactions and pain, probably by decreasing activity of enzyme cyclooxygenase, which inhibits prostaglandin synthesis. |
| Adult Dose | 200-400 mg PO q4-6h prn; not to exceed 3.2 g/d |
| Pediatric Dose | <6 years: Not established 6 months to 12 years: 20-40 mg/kg/d PO divided tid/qid >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Ketoprofen (Oruvail, Orudis, Actron) |
|---|---|
| Description | For relief of mild to moderately severe pain and inflammation. Administer small dosages initially to patients with small bodies, older persons, and those with renal or liver disease. Doses higher than 75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | <3 months: Not established 3 months to 12 years: 0.1–1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Naproxen (Anaprox, Naprelan, Naprosyn) |
|---|---|
| Description | Used for relief of mild to moderately severe pain. Inhibits inflammatory reactions and pain by decreasing activity of enzyme cyclooxygenase, which decreases prostaglandin synthesis. |
| Adult Dose | 500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
| Drug Name | Flurbiprofen (Ansaid) |
|---|---|
| Description | Has analgesic, antipyretic, and anti-inflammatory effects. May inhibit cyclooxygenase enzyme, decreasing prostaglandin biosynthesis. |
| Adult Dose | 200-300 mg/d PO divided bid/qid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
Pain control is essential to quality patient care. It ensures patient comfort, promotes pulmonary toilet, and aids physical therapy regimens. Many analgesics have sedating properties that benefit patients who have sustained fractures.
| Drug Name | Acetaminophen (Tylenol, Panadol, aspirin-free Anacin) |
|---|---|
| Description | DOC for treatment of pain in patients with documented hypersensitivity to aspirin or NSAIDs or in those with upper GI disease or taking oral anticoagulants. |
| Adult Dose | 325-650 mg PO q4-6h or 1000 mg tid/qid; not to exceed 4 g/d |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d >12 years: 325-650 mg PO q4h; not to exceed 5 doses q24h |
| Contraindications | Documented hypersensitivity; known G-6-P deficiency |
| Interactions | Rifampin can reduce analgesic effects; barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Hepatotoxicity possible in chronic alcoholics following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; acetaminophen is contained in many OTC products and combined use with these products may result in cumulative acetaminophen doses exceeding recommended maximum dose |
| Drug Name | Acetaminophen and codeine (Tylenol #3) |
|---|---|
| Description | Drug combination indicated for treatment of mild to moderately severe pain. |
| Adult Dose | 30-60 mg/dose based on codeine content PO q4-6h or 1-2 tabs q4h; not to exceed 12 tab/d |
| Pediatric Dose | 0.5-1 mg/kg/dose based on codeine content PO q4-6h; 10-15 mg/kg/dose based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen |
| Contraindications | Documented hypersensitivity |
| Interactions | CNS depressants or tricyclic antidepressants increase toxicity |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in patients dependent on opiates since this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Hydrocodone bitartrate and acetaminophen (Vicodin ES) |
|---|---|
| Description | Drug combination indicated for relief of moderately severe to severe pain. |
| Adult Dose | 1-2 tab/cap PO q4-6h prn |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d of acetaminophen >12 years: 750 mg acetaminophen PO q4h; single dose not to exceed 10 mg of hydrocodone bitartrate; not to exceed 5 doses/d |
| Contraindications | Documented hypersensitivity; high-altitude cerebral edema; elevated intracranial pressure |
| Interactions | Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants increase toxicity |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Tablets contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates since this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Oxycodone and acetaminophen (Percocet) |
|---|---|
| Description | Drug combination indicated for relief of moderately severe to severe pain. DOC for aspirin-hypersensitive patients. |
| Adult Dose | 1-2 tab/cap PO q4-6h prn |
| Pediatric Dose | 0.05-0.15 mg/kg/dose oxycodone PO q4-6h prn; not to exceed 5 mg/dose of oxycodone |
| Contraindications | Documented hypersensitivity |
| Interactions | Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants increase toxicity |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Duration of action may increase in elderly persons; be aware of total daily dose of acetaminophen patient is receiving; do not exceed 4000 mg/24 h of acetaminophen; higher doses may cause liver toxicity |
| Drug Name | Morphine sulfate (Duramorph, Astramorph, MS Contin) |
|---|---|
| Description | DOC for narcotic analgesia because of its reliable and predictable effects, safety, and ease of reversibility with naloxone. Administered IV, may be dosed in a number of ways and commonly is titrated until desired effect obtained. |
| Adult Dose | Starting dose: 0.1 mg/kg IV/IM/SC Maintenance dose: 5-20 mg/70 kg IV/IM/SC q4h Relatively hypovolemic patients: Start with 2 mg IV/IM/SC and reassess hemodynamic effects of dose |
| Pediatric Dose | Neonates: 0.05-0.2 mg/kg IV/IM/SC prn Children: 0.1-0.2 mg/kg IV/IM/SC q2-4h prn |
| Contraindications | Documented hypersensitivity; hypotension; potentially compromised airway in which establishing rapid airway control would be difficult |
| Interactions | Phenothiazines may antagonize analgesic effects; tricyclic antidepressants, MAOIs, and other CNS depressants may potentiate adverse effects |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Avoid in hypotension, respiratory depression, nausea, emesis, constipation, and urinary retention; caution in atrial flutter and other supraventricular tachycardias; has vagolytic action and may increase ventricular response rate |
Prophylaxis is given to patients with open fractures. Therapy must cover all likely pathogens in the context of the clinical setting.
| Drug Name | Penicillin G (Pfizerpen) |
|---|---|
| Description | Interferes with synthesis of cell wall mucopeptide during active replication, resulting in bactericidal activity against susceptible microorganisms. |
| Adult Dose | 2.4 million U IM as single dose in 2 injection sites |
| Pediatric Dose | 50,000 U/kg IM |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid can increase effects; tetracyclines can decrease effects |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in impaired renal function |
| Drug Name | Ceftriaxone (Rocephin) |
|---|---|
| Description | Third-generation cephalosporin that has broad-spectrum activity against gram-negative organisms, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms. By binding to one or more penicillin-binding proteins, arrests bacterial cell wall synthesis and inhibits bacterial growth. |
| Adult Dose | 1-2 g IV qd/bid for 5-7 d; not to exceed 4 g/d |
| Pediatric Dose | >7 days: 25-50 mg/kg/d IV; not to exceed 125 mg/d Infants and children: 50-75 mg/kg/d IV q12h; not to exceed 2 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase levels; ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal impairment; caution in breastfeeding women and allergy to penicillin |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Lincosamide useful as a treatment against serious skin and soft-tissue infections caused by most staphylococci strains. Also effective against aerobic and anaerobic streptococci, except enterococci. Inhibits bacterial protein synthesis by inhibiting peptide chain initiation at bacterial ribosome, where it preferentially binds to 50S ribosomal subunit, inhibiting bacterial replication. |
| Adult Dose | 600-1200 mg/d IV/IM q6-8h depending on degree of infection |
| Pediatric Dose | 20-40 mg/kg/d IV/IM tid/qid |
| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis |
This agent is used for tetanus immunization. Booster injection in previously immunized individuals is recommended to prevent this potentially lethal syndrome.
| Drug Name | Tetanus toxoid |
|---|---|
| Description | Used to induce active immunity against tetanus in selected patients. Tetanus and diphtheria toxoids are immunizing DOC for most adults and children >7 y. Necessary to administer booster doses to maintain tetanus immunity throughout life. Pregnant patients should receive only tetanus toxoid, not diphtheria antigen-containing product. In children and adults, may administer into deltoid or midlateral thigh muscles. In infants, preferred site of administration is midthigh laterally. |
| Adult Dose | Primary immunization: 0.5 mL IM, give 2 injections 4-8 wk apart and third dose 6-12 mo after second injection Booster dose: 0.5 mL q10y |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; history of any type of neurological symptoms or signs following administration of this product FDA recommends that elective tetanus immunization be deferred during any outbreak of poliomyelitis because tetanus toxoid injections are an important cause of provocative poliomyelitis |
| Interactions | Patients receiving immunosuppressants, including corticosteroids or radiation therapy, may remain susceptible despite immunization due to poor immune response; cimetidine may enhance or augment delayed-hypersensitivity responses to skin-test antigens; avoid concurrent use of medication with systemic chloramphenicol since it may impair amnestic response to tetanus toxoid; concurrent use of tetanus immune globulin may delay development of active immunity by several days (interaction is nevertheless clinically insignificant and does not preclude its concurrent use) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Do not use to treat actual tetanus infections, or for immediate prophylaxis of unimmunized individuals (use instead tetanus antitoxin, preferably human tetanus immune globulin) diminished antibody response to active immunization may be seen in patients receiving immunosuppressive therapy; better to defer primary diphtheria immunization until immunosuppressive therapy discontinued; routine immunization of symptomatic and asymptomatic HIV-infected persons recommended |
Patients who may not have been immunized against Clostridium tetani products should receive tetanus immune globulin.
| Drug Name | Tetanus immune globulin (Hyper-Tet) |
|---|---|
| Description | Used for passive immunization of any patient with a wound that may be contaminated with tetanus spores. |
| Adult Dose | Prophylaxis: 250-500 U IM in opposite extremity to tetanus toxoid Clinical tetanus: 3,000-10,000 U IM |
| Pediatric Dose | Prophylaxis: 250 U IM in opposite extremity to tetanus toxoid Clinical tetanus: 3,000-10,000 U IM |
| Contraindications | Since antibodies in globulin preparation may interfere with immune response to vaccination, do not administer within 3 mo of live virus immune globulin administration; may be necessary to revaccinate persons who received immune globulin shortly after live virus vaccination |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Persons with isolated IgA deficiency have potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA; do not perform skin testing since intradermal injection of concentrated gamma globulin may cause localized area of inflammation and can be misinterpreted, causing the medication to be withheld from a patient not allergic to this material; true allergic responses to human gamma globulin given in prescribed IM manner are extremely rare; do not admix with other medications since usually incompatible |
Article Last Updated: Mar 6, 2008